Metastatic Castration-Resistant Prostate Cancer Articles | Page 2

FDA Approval Sought for Apalutamide in Prostate Cancer
A new drug application has been submitted to the FDA for apalutamide (ARN-509) for the treatment of non-metastatic castration-resistant prostate cancer (CRPC).
FDA Approves Reduced Dose of Cabazitaxel for mCRPC
The FDA has approved a cabazitaxel (Jevtana) regimen of 20 mg/m2 every 3 weeks in combination with prednisone for the treatment of men with metastatic castration-resistant prostate cancer.
Cross-Resistance to Docetaxel and Cabazitazel in CRPC Mediated by ABCB1 Gene
Results of an investigation indicate that resistance to docetaxel and cabazitaxel (Jevtana) in patients with castration-resistant prostate cancer is mediated by a common mechanism, overexpression of the ABCB1 gene.
PROSPER CRPC Data to Be Released 2 Years Earlier Than Expected
Astellas Pharma and Pfizer have announced that phase III results from the PROSPER trial of enzalutamide (Xtandi) in men with nonmetastatic castration-resistant prostate cancer will be ready later this year.
Docetaxel Combined With Dexamethasone Shows PSA Response in Patients With CRPC
A recent phase II trial demonstrated that the combination of docetaxel-based chemotherapy and dexamethasone showed significantly high PSA responses compared with previous studies in patients with CRPC.
Raoul S. Concepcion, MD, discusses the new era of molecular testing and screening and how it has impacted the field of prostate cancer thus far. 
Researchers may be able to predict which patients with CRPC are most likely to have poorer outcomes while undergoing targeted therapy, according to the results of the PREMIERE trial.
ASCO Issues Guidance on Second-Line Treatment of CRPC
Informed by new clinical evidence, ASCO has issued updated guidance on the use of second-line hormonal therapy for chemotherapy-naïve patients with castration-resistant prostate cancer.
Next-Generation Therapies in CRPC Take Aim at AR Resistance
As a wealth of research has shown in the past several years, therapies that target the androgen receptor pathway in patients with castration-resistant prostate cancer encounter complex mechanisms of resistance including the likelihood that more than 1 such signaling network is active in each individual.
Robert Dreicer, MD, highlights several emerging treatments for patients with metastatic castration-resistant prostate cancer. 

Publication Bottom Border
Border Publication